Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | LY2603618 |
Trade Name | |
Synonyms | LY-2603618|Rabusertib |
Drug Descriptions |
Rabusertib (LY2603618) is a small molecule that inhibits CHK1, which may lead to disruption of DNA synthesis, early mitosis, and apoptosis, and may increase tumor cell sensitivity to chemotherapeutics (PMID: 24114124, PMID: 28625637). |
DrugClasses | CHK1 Inhibitor 18 |
CAS Registry Number | 911222-45-2 |
NCIT ID | C81937 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
AMT-562 + LY2603618 | AMT-562 LY2603618 | 0 | 0 |
Cisplatin + LY2603618 + Pemetrexed Disodium | Cisplatin LY2603618 Pemetrexed Disodium | 0 | 0 |
Gemcitabine + LY2603618 | Gemcitabine LY2603618 | 0 | 0 |
LB-100 + LY2603618 | LB-100 LY2603618 | 0 | 0 |
LY2603618 | LY2603618 | 0 | 0 |
LY2603618 + Pemetrexed Disodium | LY2603618 Pemetrexed Disodium | 0 | 0 |
LY2603618 + STP-B | LY2603618 STP-B | 0 | 0 |